Featured Insight
PRECISIONadvisors Recognized as a Vault Top Ranked Consulting Firm
PRECISIONadvisors has been recognized as a Vault Top Ranked Consulting Firm! This marks PRECISIONadvisors' inaugural appearance on the prestigious Vault Consulting 50 list, which evaluates firms based on confidential employee input covering aspects such as workplace culture and quality of life. The firm secured rankings in four distinct categories: Vault Consulting 50 North America Best Boutique Consulting Firms Best Consulting Firms for Women Best Consulting Firms for Formal Training
PRECISIONadvisors New Office Opening in London
The PRECISIONadvisors team is looking forward to welcoming clients and Precision colleagues to their new office opening this week. The client networking event includes a panel discussion on the evolving marketing access environment in the UK featuring Andrew Walker, David Watson and Neil Grubert. Reach out to Richard Macaulay to attend! * Schedule a meeting with one of our experts * Be sure to attend the two Podium Presentations by Precision's Richard Macaulay on November 14 and 15
Conference: ISPOR Europe 2023
Precision will be at ISPOR Europe, November 12-15, 2023. * Schedule a meeting with one of our experts * Be sure to attend the two Podium Presentations by Precision's Richard Macaulay on November 14 and 15
How High Can Prices Go? Cell and Gene Therapies
Curious how high prices can go in cell and gene therapies? Read our white paper to learn more about developments in the cell and gene therapy payer world.
China’s NRDL 2022 Update: Spotlight on Rare Disease (Part 3 of 3)
With negotiated prices as much as 95% below launch pricing, marketing rare disease therapies in China is a challenge. PRECISIONadvisors Chloe Wang, Katherine Leong, and Cherry Moldovan discuss alternate access channels. Download the free brief (part 3 of 3).
China NRDL 2022 Update – Spotlight on Oncology (Part 2 of 3)
Recent updates to China’s NRDL have a big impact on oncology therapies. PRECISIONadvisors Chloe Wang, Katherine Leong, and Cherry Moldovan explain what that means for multinationals in this free brief (part 2 of 3).
On Demand: NICE Early Scientific Advice: When, Why, and How!
Have you considered using NICE Scientific Advice (SA) to inform your evidence development, trial design, and/or economic modelling? Are you familiar with the concept of NICE SA, but have no direct experience? Or have you used the process before, but want to learn how to optimise your use of it? Join PRECISIONadvisors on July 26 at 9am EST for a complimentary webinar, as we share our experience with NICE SA in a pragmatic discussion of what it can do for you, and best practices for getting the most from NICE SA.
On Demand: Cell and Gene Therapies – How High Can Prices Go?
This ON24 webinar will discuss how cell and gene therapies can be justifiably priced at different levels. We will explore just how high they can extend and also how we can collectively ensure that patients can access these innovations when they are needed. This discussion will be led by David Carr: Senior Director, Global Pricing and Market Access (PRECISIONadvisors), Richard Macaulay: SVP, Global Pricing and Market Access (PRECISIONadvisors).
On Demand Webinar – Paying for Prevention? Payer Access Challenges and Solutions for Preventative Gene Therapies
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
How High Can Prices Go? Cell and Gene Therapies
Curious how high prices can go in cell and gene therapies? Read our white paper to learn more about developments in the cell and gene therapy payer world.
White Paper: “Preventative” Gene Therapies: Perspectives on Payer Access Challenges and Solutions
Gene therapies offer hope for patients with severe genetic diseases by providing long-term benefits and even cures. However, the challenges of evaluating the long-term benefits of these therapies from a payer perspective are considerable. This white paper by PRECISIONadvisors highlights the shift of gene therapy research into more prevalent diseases, and outlines how manufacturers and payers can co—create evidence requirements and models to optimize launch success and sustainability.
New White Paper: Speeding up Patient Access to Innovation: Strategies to Convert Early European Regulatory Approval Into Optimal Reimbursement
Efforts to facilitate patient access to innovative medicines have taken on new urgency in the pandemic era, sharpening drug developers’ focus on the first step in this process: securing regulatory approval.
PRECISIONadvisors Recognized as a Vault Top Ranked Consulting Firm
PRECISIONadvisors has been recognized as a Vault Top Ranked Consulting Firm! This marks PRECISIONadvisors' inaugural appearance on the prestigious Vault Consulting 50 list, which evaluates firms based on confidential employee input covering aspects such as workplace culture and quality of life. The firm secured rankings in four distinct categories: Vault Consulting 50 North America Best Boutique Consulting Firms Best Consulting Firms for Women Best Consulting Firms for Formal Training
PRECISIONadvisors New Office Opening in London
The PRECISIONadvisors team is looking forward to welcoming clients and Precision colleagues to their new office opening this week. The client networking event includes a panel discussion on the evolving marketing access environment in the UK featuring Andrew Walker, David Watson and Neil Grubert. Reach out to Richard Macaulay to attend! * Schedule a meeting with one of our experts * Be sure to attend the two Podium Presentations by Precision's Richard Macaulay on November 14 and 15
Conference: ISPOR Europe 2023
Precision will be at ISPOR Europe, November 12-15, 2023. * Schedule a meeting with one of our experts * Be sure to attend the two Podium Presentations by Precision's Richard Macaulay on November 14 and 15
China’s NRDL 2022 Update: Spotlight on Rare Disease (Part 3 of 3)
With negotiated prices as much as 95% below launch pricing, marketing rare disease therapies in China is a challenge. PRECISIONadvisors Chloe Wang, Katherine Leong, and Cherry Moldovan discuss alternate access channels. Download the free brief (part 3 of 3).
China NRDL 2022 Update – Spotlight on Oncology (Part 2 of 3)
Recent updates to China’s NRDL have a big impact on oncology therapies. PRECISIONadvisors Chloe Wang, Katherine Leong, and Cherry Moldovan explain what that means for multinationals in this free brief (part 2 of 3).
China’s NRDL 2022 Update: A Snapshot and Overall Trends (Part 1 of 3)
In China’s rapidly growing pharma market, the NRDL is the main path to market access. And it’s changed. PRECISIONadvisors Chloe Wang, Katherine Leong, and Cherry Moldovan explain what the updates mean for multinationals in this free brief (part 1 of 3).
White Paper: “Preventative” Gene Therapies: Perspectives on Payer Access Challenges and Solutions
Gene therapies offer hope for patients with severe genetic diseases by providing long-term benefits and even cures. However, the challenges of evaluating the long-term benefits of these therapies from a payer perspective are considerable. This white paper by PRECISIONadvisors highlights the shift of gene therapy research into more prevalent diseases, and outlines how manufacturers and payers can co—create evidence requirements and models to optimize launch success and sustainability.
What Changes Can We Expect on Health Care in the Coming General Elections in Spain?
What changes can we expect on health care in the coming general elections in Spain? Following up on our previous post, we have some insights on what lies ahead for the coming general elections in Spain.
On Demand: NICE Early Scientific Advice: When, Why, and How!
Have you considered using NICE Scientific Advice (SA) to inform your evidence development, trial design, and/or economic modelling? Are you familiar with the concept of NICE SA, but have no direct experience? Or have you used the process before, but want to learn how to optimise your use of it? Join PRECISIONadvisors on July 26 at 9am EST for a complimentary webinar, as we share our experience with NICE SA in a pragmatic discussion of what it can do for you, and best practices for getting the most from NICE SA.
What you need to know about key stakeholders and P&MA dynamics in Latin America for 2023 and beyond
Latin America is a $43 billion pharma market—and regional dynamics matter. PRECISIONadvisor’s dedicated team of experts can help navigate local market access and pricing. Discover what that means for your brand.
Hear From Key Stakeholders: The Future Treatment and Access Landscape for Cell & Gene Therapies Roundtable
Earlier this year, Precision Value & Health, in association with Precision ADVANCE, hosted an in-depth, live roundtable: The Future Treatment and Access Landscape for Cell and Gene Therapies
Hear From Key Stakeholders: The Future Treatment and Access Landscape for Cell & Gene Therapies Roundtable
Earlier this year, Precision Value & Health, in association with Precision ADVANCE, hosted an in-depth, live roundtable: The Future Treatment and Access Landscape for Cell and Gene Therapies
FDA announces launch of Project FrontRunner
Earlier this year, the FDA announced plans to launch Project FrontRunner to support manufacturers in prioritizing the development of cancer drugs in early treatment lines, partly in response to issues that have arisen with the current accelerated approval scheme. In this #Access90 video, Precision's Dominika Meszarosova discusses the issues that Project Frontrunner seeks to address and the critical need for early dialogue, incentives and close collaboration with manufacturers to ensure success.
Key Takeaways From the World Evidence, Pricing and Access Congress 2022
Did you miss this years World EPA Congress? Checkout this free, downloadable PDF that provides a summary of the PRECISIONadvisors presentation "Gene Therapies Market Access: Lessons From the Past, Future Best Practice", as well as other key takeaways from the conference including initiatives to support improved patient access, access challenges, and more.
Accounting for inflation within NICE cost-effectiveness thresholds
Why are some drugs that may be demonstrated as cost-effective not being recommended for reimbursement? PRECISIONadvisors Richard Macaulay and his co-author have published this influential study, uncovering that the NICE ICER thresholds have declined by 42.9% in real terms since 2004 (without accounting for inflation).
On-Demand Webinar: Continuing the Conversation-The Future of Reimbursement for Cell and Gene Therapies
Join us for this webinar, which will bring payer representatives from the UK (Andrew Walker), Germany (Frank-Ulrich Fricke), and Italy (Gianluigi Casadei) alongside an industry representative to discuss how payers will respond to this changing C> landscape and how manufacturers can proactively mitigate their strategies.
On-Demand Webinar: Oncology Care in a Value-Based World
Join us for the webinar Oncology Care in a Value-Based World which will highlight the activities and needs of payers and providers as they strive to deliver high-quality oncology care in a value-based environment. In this presentation, KOLs with market access, population health, and EMR experience will share the ways in which payers and health systems are supporting a value-based approach to oncology through care initiatives, technology, and access to innovative therapies.
On-demand Webinar: Considerations for Internal Versus External Manufacturing for Developing Cell and Gene Therapies
Manufacturing has been widely recognized as a bottleneck to bring advanced cell and gene therapies to the patients and families in need. The question is, should organizations stay the course internally, or look externally for their manufacturing needs?
On-demand Webinar: Wish I Knew Then What I Know Now–How Cell and Gene Therapies are Reshaping Commercialization Strategies
In this webinar, Carolyn Morgan of PRECISIONeffect moderates an expert panel exploring the challenges of commercializing a cell or gene therapy from industry trailblazers.
On-demand Webinar: Gene Therapies In Hemophilia
Onetime, potentially curative treatments for hemophilia represent the first 'big wave' in the gene therapy space. Moderated by Larry Blandford of PRECISIONvalue, join us as we explore the challenges, and discuss solutions to getting new and innovative gene therapy therapies into the hands of patients who need them most.
On-demand Webinar: Optimizing Product Launch Market Access strategy and Gross-to-Net Modeling
Join Precision and Akara Group for a special, online discussion of best practices for pre-launch commercialization activities.
Access90: Chloe Wang
For pharma companies, NRDL is the primary route of reimbursement in China—and the rules have changed. Find out how, in this 2-minute video with Chloe Wang, PRECISIONadvisors Analyst and a member of the China Centre of Excellence.
Download Now: Precision June Events Calendar
The June Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
Access90: Salvador Alvarez Rio
With the Latin American pharma market expected to grow 10% in the next two years, it pays to gain access. But how? Salvador Alvarez Rio, Senior Engagement Manager at PRECISIONadvisors, explains the power of patient advocacy groups to insist on reimbursement for high-cost advanced medicines.
Access90: William Derrickson
Dystrophic Epidermolysis Bullosa (DEB) is an ultra rare genetic disease with no currently approved treatments. In this Access90, Precision's Will Derrickson discusses the unique market access considerations for Krystal Biotech's anticipated launch of B-VEC, a non-invasive treatment for DEB and the first ever topical gene therapy.
Download Now: Precision May Events Calendar
The May Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
Access90: Katherine Ka Wan
With the MHRA becoming the standalone regulator of medicines in Great Britain, Precision research aims to shed light on market access in the post-Brexit era, as well as key implications for manufacturers. In this Access90, Precision's Katherine Ka Wan Leong discusses two research posters the PRECISION team will be presenting at ISPOR US this year focusing on the UK access landscape.
